Wegovy Flextouch (2.4mg)

Wegovy Flextouch (2.4mg)

SKU: wegovy-24

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions using the Yellow Card Scheme: www.mhra.gov.uk/yellowcard

Wegovy (2.4mg) comes with 4 Novofine needles as supplied by the manufacturer

Additional safe guidelines:- when prescribing Wegovy adults should have a BMI over 30, or those with a BMI of 27+ with at least one weight-related condition.BMI must be stated on the prescription and only x2 pens per patient per prescription. 

EMC: https://www.medicines.org.uk/emc/product/13803

Patient Information Leaflet: https://www.medicines.org.uk/emc/files/pil.13799.pdf

Login for price

Description

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions using the Yellow Card Scheme: www.mhra.gov.uk/yellowcard

Wegovy (2.4mg) comes with 4 Novofine needles as supplied by the manufacturer

Additional safe guidelines:-

When prescribing Wegovy adults should have a BMI over 30, or those with a BMI of 27+ with at least one weight-related condition.BMI must be stated on the prescription and only x2 pens per patient per prescription. 

Please note safe disposal of needles is required where necessary, we stock 1 litre sharps bins, please add at check out.

EMC: https://www.medicines.org.uk/emc/product/13803

Patient Information Leaflet: https://www.medicines.org.uk/emc/files/pil.13799.pdf

Description

Wegovy (Semaglutide) 2.4mg FlexTouch solution for injection in pre-filled pen

Wegovy is a prescription only medicine indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of

  • ≥ 30 kg/m2 (obesity), or
  • ≥ 27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).

Mechanism of action:

Semaglutide is a GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.

GLP-1 is a physiological regulator of appetite and calorie intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation.

Semaglutide has direct effects on areas in the brain involved in homeostatic regulation of food intake in the hypothalamus and the brainstem, and direct and indirect effects on areas involved in hedonic regulation of food intake, including the septum, thalamus and amygdala.

Contraindications:

Hypersensitivity to the active substance or to any of the excipients.

Store in a refrigerator at 2–8°C

Additional information

Purchase Option

item(s) in basket

Open chat
Welcome to Smile Pharma.
Our office hours are:
9am - 5pm Mon to Thur
9am - 4:30pm Friday

Outside of these hours please send an email to [email protected]